Healthcare Industry News:  Orthofix 

Devices Orthopaedic Personnel

 News Release - November 14, 2007

Advanced Bio-Surfaces Announces New CEO

Experienced CEO is ready to drive company's commercialization

MINNEAPOLIS, Nov. 14 (HSMN NewsFeed) -- Advanced Bio-Surfaces, Inc., (ABS) announced today that David Lorenzi has joined the company as its new President and Chief Executive Officer. Mr. Lorenzi will also serve as a member of the ABS Board of Directors. The company's founder and former CEO, Jeffrey Felt, M.D. will serve as Chairman and Chief Technology Officer.

Mr. Lorenzi is a seasoned executive with expertise in leading the commercial growth of orthopedic medical devices companies. ABS Founder, Dr. Jeff Felt praised David's acumen, citing his "established record of bringing focus to organizations and his reputation as a leader possessing both the experience and drive needed to lead ABS to profitability. ABS will benefit greatly from these qualities."

Mr. Lorenzi's experience includes roles as President and Chief Executive Officer for both OMNI life science, Inc. and PLUS Orthopedics USA, Inc.. Both companies focus on the orthopedic segment of healthcare, primarily with joint reconstruction products. In addition to OMNI life science and PLUS Orthopedics, David has also held various field, senior and executive level management positions with Ethicon, Orthofix, EMPI and Medtronic. He has participated as a member of the Board of Directors of PLUS Orthopedics, Inc., OMNI life science, Inc. and Enztec, Ltd.

"I am very excited to be part of ABS," said David Lorenzi. "The company has developed a pipeline of unique products that address the unmet needs of orthopedic surgeons and their patients. I look forward to working with Dr. Jeff Felt and the management team to build a strong business that achieves our strategic objectives and maximizes value for our shareholders."

About Advanced Bio-Surfaces, Inc.

ABS is a privately held company dedicated to the development of innovative joint restoration products. The company's first product, the OrthoGlide Medial Knee Implant, is intended for the treatment of patients with moderate osteoarthritis of the medial compartment. The company received 510(k) clearance to market from the U.S. Food and Drug Administration (FDA) and CE mark notification from its Notified Body, in February 2006. For additional information contact ABS at 952.912.5400 or visit the website at

Source: Advanced Bio-Surfaces

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.